Inflammasome activation in infected macrophages drives COVID-19 pathology

References 85

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.
   Type I IFN Triggers RIG-I/TLR3/NLRP3-dependent Inflammasome Activation in Influenza A Virus Infected Cells · 2013

   No notice
6. 6.
   HTSeq—a Python framework to work with high-throughput sequencing data · 2014

   No notice
7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.
    Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 2014

    No notice
11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.
    MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice · 2018

    No notice
15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.
    Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR · 2020

    Expression of concern
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.
    Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction · 2020

    No notice
27. 27.
    Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir · 2020

    No notice
28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.
    Two distinct immunopathological profiles in autopsy lungs of COVID-19 · 2020

    No notice
35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.
    Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients · 2020

    No notice
40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 8

• Updated insights into the molecular networks for NLRP3 inflammasome activation · 2025
  No notice
• The role of inflammasomes in human diseases and their potential as therapeutic targets · 2024
  No notice
• cGAS-STING, inflammasomes and pyroptosis: an overview of crosstalk mechanism of activation and regulation · 2024
  No notice
• The role of NOD-like receptors in innate immunity · 2023
  No notice
• Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages · 2022
  No notice
• Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes · 2022
  Not checked
• SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein · 2022
  No notice
• The development and improvement of immunodeficient mice and humanized immune system mouse models · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.